Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May 1;93(9):754-755.
doi: 10.1016/j.biopsych.2023.02.003.

Proteomic Data Advance Targeted Drug Development for Neurogenerative Diseases

Nora E Emerson  1 , Vivek Swarup  2
Affiliations
Comment

Proteomic Data Advance Targeted Drug Development for Neurogenerative Diseases

Nora E Emerson et al. Biol Psychiatry. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Acknowledgements and Disclosures

The authors report no biomedical financial interests or potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Blood and brain proteomic data was taken from databases and put through mendelian randomization. After further statistical testing (for example, colocalization), possible targets were analyzed for safety, druggability and causation using various metrics, in hopes of creating a pipeline to reduce costs and time of sorting through large data sets. This resulted in 22 possible drug targets for further research.
See this image and copyright information in PMC

Comment on

References

    1. Ge Y, Ou Y, Deng Y, Wu B, Yang L, Zhang Y, et al. (2022): Prioritization of drug targets for neurodegenerative diseases by integrating genetic and proteomic data from brain and blood. Biol Psychiatry - PubMed
    1. Davies NM, Holmes MV, Smith GD (2018): Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ, 362. - PMC - PubMed
    1. Emmerich CH, Gamboa LM, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, et al. (2021): Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov 20: 64–81. - PMC - PubMed
    1. Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A (2022): Progranulin as a therapeutic target in neurodegenerative diseases. Trends in Pharmacological Sciences 43;8: 641–652. - PubMed
    1. Petkau TL, Leavitt BR (2014): Progranulin in neurodegenerative disease. Trends in Neurosciences 37;7: 388–398. - PubMed

Publication types